
|Articles|November 1, 2004
Plans review pediatric antidepressant use in wake of FDA label change
By withholding information about some antidepressant medications that cause an increase in suicidal tendencies among teenagers, the Food and Drug Administration (FDA) created heightened public concern about the value of antidepressants.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Myqorzo is now available for rare heart condition at a $108,400 annual price
2
PBM reform. It has finally happened
3
Melanoma diagnoses projected to rise in 2026
4
ACHP announces new funding to elevate patient voices in diabetes research
5























